Postnatal Expression of BRAFV600E Does Not Induce Thyroid Cancer in Mouse Models of Thyroid Papillary Carcinoma

Author(s)
Shimamura, Mika; Nakahara, Mami; Orim, Florence; Kurashige, Tomomi; Mitsutake, Norisato; Nakashima, Masahiro; Kondo, Shinji; Yamada, Masanobu; Taguchi, Ryo; Kimura, Shioko; Nagayama, Yuji

Citation
Endocrinology, 154(11), pp.4423-4430; 2013

Issue Date
2013-11-01

URL
http://hdl.handle.net/10069/34212

© 2013 by The Endocrine Society.
The legends for supplement figures

Supplement Figure 1. Thyroid histology of control #213MM and #213MM mice injected with Ad-TgP-Cre at 4 weeks of age. Representative data at 12th and 52nd weeks were shown.

Supplement Figure 2. The lentivirus vectors, V5 expression and H&E histology of the thyroids from TPO-Cre mice mock-injected or injected with the lentivirus. (A) The structures of the lentivirus vectors, LEL-BRAFV600E-V5 and LEL-LacZ-V5. (B) Immunohistochemistry of V5 expression in the thyroids of TPO-Cre mice mock-injected or injected with the lentivirus. (C) H&E staining of the thyroids of TPO-Cre mice mock-injected or injected with the lentivirus 48 weeks after injection.
A control #213

B #213 injected with Ad-TgP-Cre

C wt mice injected with Ad-TgP-Cre

12 wks 52 wks
wks after injection

Shimamura et al. supplement Fig. 1
A

CMV promoter loxP EGFP loxP BRAF^{V600E} V5

CMV promoter loxP EGFP loxP LacZ V5

B

control  LEL-BRAF^{V600E} V5  LEL-LacZ-V5

C

LEL-LacZ-V5  LEL-BRAF^{V600E} V5

Shimamura et al. supplement Fig. 2